Biologic immunomodulatory therapies in the vasculitic diseases

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 5, 2004, Pages 595-607

  Langford, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biologic; Monoclonal; Recombinant; Treatment; Vasculitis

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB;

BLOOD TOXICITY; BONE MARROW TOXICITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CRYOGLOBULINEMIA; DEMYELINATING DISEASE; DEPRESSION; DISEASE ACTIVITY; DRUG SAFETY; EYE INFLAMMATION; HEART FAILURE; HISTOPLASMOSIS; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; LISTERIOSIS; LYMPHOCYTOPENIA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PATIENT SELECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RELAPSE; REVIEW; SEPSIS; SIDE EFFECT; TUBERCULOSIS; TUMOR LYSIS SYNDROME; VASCULITIS;

EID: 8744285775     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836150     Document Type: Review

References (139)

1. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-211
2. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum 2002;46:1984-1985
3. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-1702
4. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-1983
5. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53:457-465
6. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-1888
7. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534
8. Sneller MC. Granuloma formation, implications for the pathogenesis of vasculitis. Cleve Clin J Med 2002;69 (suppl 2):SII40-SII43
9. Ludviksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-3609
10. Csernok E, Trabandt A, Müller A, et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999;42:742-750
11. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-1154
12. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-1307
13. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002;61:559
14. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-1132
15. Russell KA, Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. Rheum Dis Clin North Am 2001;27:815-832
16. Preston GA, Yang JJ, Xiao H, Falk RJ. Understanding the pathogenesis of ANCA: where are we today? Cleve Clin J Med 2002;69(suppl 2):SII51-SII54
17. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-963
18. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-2840
19. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341:1620-1622
20. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996;89:903-912
21. Jayne DRW. CAMPATH-1H (anti-CD-52) for refractory vasculitis: retrospective Cambridge experience 1989-1999. Cleve Clin J Med 2002;69(suppl 2):SII-129
22. Mathieson PW, Cobbold SP, Hale G, et al. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 1990;323:250-254
23. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 1951;27:277-301
24. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003;21(6 suppl 32):S69-S77
25. Kiene M, Csernok E, Muller A, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001;44:469-473
26. Bockenstedt PL, Santinga JT, Boiling SF. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994;45:248-251
27. Mohr C, Schutte B, Hildebrand A, Luger TA, Kolde G. Eosinophilic pustular folliculitis: successful treatment with interferon-alpha. Dermatology 1995;191:257-259
28. Husak R, Goerdt S, Orfanos CE. Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection. N Engl J Med 1997;337:641-642
29. Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for Interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood 1996;87:2354-2360
30. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998;129:370-374
31. Lesens O, Hansmann Y, Nerson J, et al. Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur J Intern Med 2002;13:458
32. Kroegel C, Mock B, Reissig A. Interferons and their application in lung diseases. Chest 2003;124:2406-2407
33. Termeer CC, Simon JC, Schopf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 2001;137:136-138
34. Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004;5:25-35
35. Arbach O, Gross WL, Cause A. Treatment of refractory Churg-Strauss- Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002;206:496-501
36. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-169
37. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-515
38. Brack A, Geisler A, Martinez-Taboada VM, et al. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997;3:530-543
39. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-2935
40. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:1116
41. Airo P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002;41:347-349
42. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-374
43. Agnello V, Romain PL. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheum Dis Clin North Am 1996;22:1-21
44. Sneller MC, Fauci AS. Pathogenesis of vasculitis syndromes. Med Clin North Am 1997;81:221-242
45. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999;13:1315-1349
46. Lamprecht P, Cause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999;42:2507-2516
47. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002;46:585-597
48. Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987;83:726-730
49. Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991;78:3142-3147
50. Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13(suppl 13):S175-S180
51. Cresta P, Musset L, Cacoub P, et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999;45:122-128
52. Mazzaro C, Lacchin T, Moretti M, et al. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13(suppl 13):S181-S185
53. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-3873
54. Pellicano R, Marietti G, Leone N, et al. Mixed cryoglobulinaemia associated with hepatitis C virus infection: a predictor factor for treatment with interferon? J Gastroenterol Hepatol 1999;14:1108-1111
55. Cohen P, Nguyen QT, Deny P, et al. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies: a prospective study on 20 patients. Ann Med Interne (Paris) 1996;147:81-86
56. Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 1997;27:63-71
57. Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999;13:1179-1186
58. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-756
59. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, cross-over-controlled trial. Blood 1993;81:1132-1136
60. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-3343
61. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432
62. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492
63. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-3326
64. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000;27:2172-2178
65. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
66. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355
67. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
68. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-3826
69. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-3834
70. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody-mediated autoimmune disorders with an anti-CD20 monoclonal antibody (riruximab). Am Rheum Dis 2002;61:922-924.
71. Lamprecht P, Lerin-Lozano C, Merz H; et al. Rituximab induces remission in refractory HGV-associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003;62:1230-1233
72. Gocke DJ, Hsu K, Morgan C, et al. Association between polyarteritis and Australia antigen. Lancet 1970;2:1149-1153
73. Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970;19:410-411
74. Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994;53:334-337
75. Nakamura H, Shimizu T, Ohshiro S, et al. An adult patient with acute hepatitis type B which was protracted and complicated by polyarteritis nodosa: a case report. Hepatol Res 2002;24:439-444
76. Duzova A, Bakkaloglu A, Yuce A, Ozen S, Kocak N. Successful treatment of polyarteritis nodosa with interferon alpha in a nine-month-old girl. Eur J Pediatr 2001;160:519-520
77. Deleaval P, Stadler P, Descombes E, et al. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol 2001;20:290-292
78. Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Haussinger D. Successful treatment of hepatitis B virus-associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon, and lamivudine. J Hepatol 2000;33:677-683
79. Wicki J, Olivieri J, Pizzolato G, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) 1999;38:183-185
80. Molloy PJ, Friedlander L, Van Thiel DH, Kania RJ. Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa. Hepatogastroenterology 1999;46:2529-2531
81. Avsar E, Savas B, Tozun N, Ulusoy NB, Kalayci C. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998;28:525-526
82. Kruger M, Boker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997;26:935-939
83. Sonntag KC, Schwarz-Eywill M, Hunstein W. Is interferon alpha a therapy for hepatitis B-associated polyarteritis nodosa? Br J Rheumatol 1995;34:486-487
84. Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol 1995;20:263-265
85. Darras-Joly C, Lortholary O, Cohen P, Brauner M, Guillevin L. Regressing microaneurysms in 5 cases of hepatitis B virus-related polyarteritis nodosa. J Rheumatol 1995;22:876-880
86. Mouthon L, Deblois P, Sauvaget F, et al. Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy. Am J Nephrol 1995;15:266-269
87. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999;42:1967-1974
88. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-132
89. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(suppl 2):ii51-ii53
90. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-296
91. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644
92. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-561
93. Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Adv Exp Med Biol 2003;528:557-559
94. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001;60:637
95. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001;40:473-474
96. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 2003;49:599-600
97. Gulli S, Arrigo C, Bocchino L, et al. Remission of Behçet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003;4:19
98. Behrens F, Zollner T, Moeller B, et al. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease. Adv Exp Med Biol 2003;528:561-562
99. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002;41:1213-1214
100. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002;61:283-284
101. Mussack T, Landauer N, Ladurner R, et al. Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab. Am J Gastroenterol 2003;98:703-704
102. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46:118-121
103. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-999
104. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-728
105. Licata G, Pinto A, Tuttolomondo A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003;62:280-281
106. Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis Ch C. Serum of patients with Behçet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003;206:225-232
107. Kotter I, Gunaydin I, Treusch M, et al. The use of interferon-alpha in Behçet's disease: review of the literature and possible mechanisms of action. Adv Exp Med Biol 2003;528:503-509
108. Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease. Clin Exp Immunol 1990;79:28-34
109. Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease. Adv Exp Med Biol 2003;528:511-519
110. Krause L, Hoffmann F, Zouboulis CC, Foerster MH. Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades- Behçet's disease: a case report. Graefes Arch Clin Exp Ophthalmol 2003;241:871-874
111. Deuter CM, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Behçet's disease: visual acuity after 5 years in patients with alpha-interferon treatment. Adv Exp Med Biol 2003;528:525-528
112. Strohal R, Tschachler E, Breyer S, et al. Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen. Br J Haematol 1998;103:788-790
113. O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behçet's disease. J Rheumatol 1998;25:1938-1944
114. Kotter I, Eckstein AK, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998;82:488-494
115. Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 2002;4(11 Suppl):928-930
116. Calguneri M, Ozturk MA, Ertenli I, et al. Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study. Ann Rheum Dis 2003;62:492-493
117. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behçet disease. J Neuroophthalmol 2001;21:109-111
118. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301
119. Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 2000;84:1437-1438
120. Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behçet's disease. Dermatology 2000;201:40-43
121. Kotter I, Aepinus C, Graepler F, et al. HHV8-associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha. Ann Rheum Dis 2001;60:83-86
122. Aoki T, Tanaka T, Akifuji Y, et al. Beneficial effects of interferon-alpha in a case with Behçet's disease. Intern Med 2000;39:667-669
123. Kosar A, Haznedaroglu S, Karaaslan Y, et al. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatol Int 1999;19:11-14
124. Georgiou S, Monastirli A, Pasmatzi E, et al. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med 1998;243:367-372
125. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon alpha for ocular Behçet's disease. Acta Ophthalmol Scand 1997;75:720-722
126. Kotter I, Durk H, Eckstein A, et al. Erosive arthritis and posterior uveitis in Behçet's disease: treatment with interferon alpha and interferon gamma. Clin Exp Rheumatol 1996;14:313-315
127. Azizlerli G, Sarica R, Kose A, et al. Interferon alfa-2a in the treatment of Behçet's disease. Dermatology 1996;192:239-241
128. Munke H, Stockmann F, Ramadori G. Possible association between Behçet's syndrome and chronic hepatitis C virus infection. N Engl J Med 1995;332:400-401
129. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease. J Am Acad Dermatol 1994;31:617-619
130. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MS. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 1994;343:1428
131. Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 1994;21:1098-1100
132. Durand JM, Kaplanski G, Telle H, Soubeyrand J, Paulo F. Beneficial effects of interferon-alpha 2b in Behçet's disease. Arthritis Rheum 1993;36:1025-1026
133. Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335-336
134. Grimbacher B, Wenger B, Deibert P, et al. Loss of vision and diarrhoea. Lancet 1997;350:1818
135. Durusoy C, Alpsoy E, Yilmaz E. Pityriasis rosea in a patient with Behçet's disease treated with Interferon alpha 2A. J Dermatol 1999;26:225-228
136. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-1016
137. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-471
138. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-431
139. Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003;42:1539-1544